4//SEC Filing
Fairman Jeff 4
Accession 0001209191-22-049025
CIK 0001649094other
Filed
Sep 6, 8:00 PM ET
Accepted
Sep 7, 4:37 PM ET
Size
9.8 KB
Accession
0001209191-22-049025
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Fairman Jeff
VP, Research
Transactions
- Sale
Common Stock
2022-09-06$26.54/sh−4,664$123,774→ 301,563 total(indirect: By Trust) - Tax Payment
Common Stock
2022-09-02$26.38/sh−519$13,691→ 17,143 total - Sale
Common Stock
2022-09-06$27.14/sh−336$9,118→ 301,227 total(indirect: By Trust)
Holdings
- 50,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
- [F2]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $26.04 to $27.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $27.09 to $27.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001813800
Filing Metadata
- Form type
- 4
- Filed
- Sep 6, 8:00 PM ET
- Accepted
- Sep 7, 4:37 PM ET
- Size
- 9.8 KB